| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Diversa Corporation |
| 10665 Sorrento Valley Road, San Diego, CA 92121 * (858) 623-5106 |
| Business Description | The company is the global leader in discovering and developing novel enzymes and other biologically active compounds from diverse environmental sources for use in agricultural, chemical processing, industrial and pharmaceutical applications. |
| Offering Information Company has | |||
| Trading As | DVSA (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 12/15/99 |
| Domestic Shares Offered | 7,250,000 | Offer Date | 2/14/00 |
| Foreign Shares Offered | 0 | Filing Range | $20.00 - $22.00 |
| Company Shares | 7,250,000 | Offer Price | $24.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.680 |
| Gross Proceeds | $174,000,000 | Selling | $1.000 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | - - | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Bear, Stearns & Co. Inc. | Lead Manager | (212) 272-4850 |
| Deutsch Banc Alex. Brown | Co-manager | (410) 727-1700 |
| Hambrecht & Quist Incorporated | Co-manager | (415) 439-3626 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 9/30/98 | 9/30/99 | |
| Revenues | - | 0.025 | 0.706 | 1.155 | 1.347 | 0.807 | 6.455 |
| Income from Oper. | - | -8.832 | -11.419 | -11.615 | -12.189 | -9.634 | -5.984 |
| Net Income | - | -8.904 | -11.646 | -11.707 | 11.845 | -9.331 | -5.803 |
| E.P.S | - | -2.560 | -2.670 | -2.530 | -2.330 | -1.790 | -0.890 |
| Revenue Growth (%) | - | 2,724.00 | 63.60 | 16.623 | 699.88 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | 879.36 | - | - |
| Cash Flow - Oper. | -10.82 | -8.89 | -1.33 | ||||
| Cash Flow - Inv. | -1.91 | -1.10 | -5.79 | ||||
| Cash Flow - Fin. | 0.59 | 0.50 | 6.57 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/99 | Financial Ratios | ||||
| Total Assets | 13.07 | Current Assets | 10.29 | Current Ratio | 2.21 |
| Total Liab. | 55.77 | Current Liab. | 4.66 | Debt Ratio | 426.60% |
| Total Equity | -42.69 | Working Cap. | 5.63 | Debt to Equity Ratio | - |
| Cash | 3.92 | Return on Assets | 90.61% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development, capital expenditures, working capital and general corporate purposes and possible acquisitions. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Brobeck, Phleger & Harrison |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Funds affiliated with HealthCare Ventures | 22.60 | |
| Funds affiliated with Patricof & Co. Ventures, Inc. | 18.30 | |
| Rho Management Trust II | 9.30 | |
| State of Michigan | 8.10 | |
| Novartis Agribusiness Biotechnology Research, Inc. | 7.60 | |
| Note: represents ownership of 5% or more prior to the offering. | ||